Endocrinology Research and Practice
Poster Presentation

Association of Serum Betatrophin with Fibroblast Growth Factor-21 in Women with Polycystic Ovary Syndrome

1.

Gazi University Facutly of Medicine, Department of Internal Medicine, Ankara, Turkey

2.

Gazi University Facutly of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Ankara, Turkey

3.

Gazi University Facutly of Medicine, Department of Medical Biochemistry, Ankara, Turkey

Endocrinol Res Pract 2018; 22: Supplement S63-S63
DOI: 10.25179/tjem.20182202-P171
Read: 1385 Downloads: 526 Published: 01 June 2018

Abstract

Betatrophin and fibroblast growth factor-21 (FGF-21), as recently discovered members of hepatokine/adipokine family, have been proposed to be associated with some metabolic disorders in which insulin resistance plays a major role. We aimed to investigate serum betatrophin and FGF- 21 concentrations in women with polycystic ovary syndrome (PCOS). In this cross-sectional study, we recruited 34 women with
PCOS and 31 women as healthy controls. Serum betatrophin level and its relationship with serum FGF-21 level as well as other metabolic parameters were examined. Serum betatrophin level was significantly higher in women with PCOS than the control group (1.10 (0.20-4.20) vs 0.70 (0.20-3.50) ng/ml, p=0.004), whereas, FGF-21 did not differ between the groups (74.80 (7.80-435.90) vs 119.30 (10.50-443.40) pg/ml, p=0.13). Serum betatrophin correlated positively with LH levels (r=0.26, p=0.03). After controlling BMI, there was a significant positive correlation between betatrophin and FGF-21 (r=0.25, p=0.04). Multivariate regression analysis revealed that FGF-21 and presence of PCOS were the significant predictors of betatrophin concentrations (R2=0.22, F=2.56, p=0.03). Our results indicate that betatrophin levels are increased and associated with LH and FGF-21 levels, not insulin resistance, in women with PCOS.
 

Files
EISSN 2822-6135